Sickle cell disease is a ~100,000-patient US population defined by genotype severity, recurrent vaso-occlusive crises and cumulative organ damage — and a 22-year life-expectancy gap that hydroxyurea only partly closes.
Sickle cell disease is an inherited hemoglobinopathy affecting roughly 100,000 Americans, occurring in about 1 in 365 Black or African American births. The homozygous HbSS genotype (sickle cell anemia) accounts for around 60–65% of cases and carries the most severe phenotype; HbSC disease (~25%) and HbS/β-thalassemia (the remainder) are generally milder, with severity tracking residual β-globin production. Polymerisation of deoxygenated hemoglobin S deforms red cells, driving hemolysis, vaso-occlusion and progressive endothelial and organ injury from early childhood.
The clinical signature is the recurrent vaso-occlusive crisis, layered over cumulative damage: acute chest syndrome, stroke, pulmonary hypertension, and renal decline. A US modelling study estimated median life expectancy at about 54 years versus 76 years without SCD, a 22-year gap. Hydroxyurea reduces crises and mortality but reaches only 25–30% of eligible patients, the single largest treatment gap in the disease. An estimated 20,000–30,000 patients with severe, recurrent vaso-occlusive disease form the subset for whom one-time gene therapy is clinically relevant — the population that now anchors commercial and access strategy.
US sickle cell disease — genotype spectrum, prevalence and burden
| Genotype / Segment | Share of US SCD | Prevalence (US est.) | Clinical Severity | Key Burden |
|---|---|---|---|---|
| HbSS (sickle cell anemia, homozygous) | ~60–65% | ~60,000–65,000 | Most severe | Frequent VOCs, acute chest syndrome, stroke, cumulative organ damage |
| HbSC disease | ~25% | ~25,000 | Milder | Retinopathy, VOCs, avascular necrosis |
| HbS/β-thalassemia | ~8–10% | ~8,000–10,000 | Variable (β0 severe, β+ milder) | Anemia, VOCs; severity tracks residual β-globin |
| Total diagnosed US SCD | 100% | ~100,000 | — | Median life expectancy ~54 yrs (22-yr gap); ~25–30% on hydroxyurea |
| Severe subset (gene-therapy-relevant) | ~20–30% of SCD | ~20,000–30,000 | Severe / recurrent VOC | ≥2 severe VOCs/yr; clinically relevant for one-time gene therapy |
Sources: Hassell KL, Am J Prev Med 2010 (PMID 20331952); Lubeck D et al., JAMA Netw Open 2019 (PMID 31730182); CDC Sickle Cell Disease surveillance data; ASH 2020 SCD guidelines. Genotype shares are triangulated estimates from US newborn-screening and surveillance data.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- US prevalence (~100,000)
- HbSS / HbSC / HbS-β-thalassemia genotype shares
- demographic concentration
- the severe subset eligible for gene therapy
Delivers
- VOC frequency and acute complications (acute chest syndrome, stroke)
- chronic organ damage
- the 22-year life-expectancy gap and its drivers
Delivers
- Hydroxyurea 25–30% utilisation gap
- newborn-screening and diagnosis pathway
- the 20,000–30,000 severe patients relevant for one-time gene therapy
Custom assessment delivered in 72 hours.
Commission This AssessmentWhat's inside
- HbSS accounts for 60–65% of US cases and carries the most severe phenotype; HbSC (~25%) and HbS/β-thalassemia are generally milder
- How polymerisation of deoxygenated hemoglobin S drives hemolysis, vaso-occlusion and progressive organ injury from early childhood
- Roughly 100,000 Americans live with SCD, occurring in about 1 in 365 Black or African American births
- Genotype-level prevalence: ~60,000–65,000 HbSS, ~25,000 HbSC, and 8,000–10,000 HbS/β-thalassemia patients
- The recurrent vaso-occlusive crisis is the clinical signature, layered with acute complications including acute chest syndrome and stroke
- HbSC patients face a distinct acute burden of retinopathy and avascular necrosis alongside vaso-occlusive crises
- Cumulative organ injury includes pulmonary hypertension and progressive renal decline building on early-childhood vaso-occlusion
- Median life expectancy is projected at about 54 years versus 76 years without SCD, a 22-year gap
- Hydroxyurea reduces crises and mortality but reaches only 25–30% of eligible patients, the largest treatment gap in the disease
- An estimated 20,000–30,000 patients with severe, recurrent vaso-occlusive disease form the population that anchors gene-therapy commercial strategy
- Why closing the diagnosis-to-treatment gap matters most for the estimated 100,000 Americans living with SCD, concentrated in the Black and African American population
- The same 25–30% hydroxyurea treatment gap leaves most eligible patients without disease-modifying therapy despite decades of availability
Included with every brief
How AXLRx builds this assessment
Prepared by MoatRx analysts.
Every AXLRx assessment is built from primary regulatory sources (FDA Drugs@FDA, ClinicalTrials.gov), peer-reviewed literature, and live payer and HTA documentation — not secondary summaries, market-research reports, or unverified estimates. Findings are independently verified before inclusion; if a figure cannot be sourced to a live record, it does not ship.
US Sickle Cell Disease Disease Landscape sources: peer-reviewed epidemiology and outcomes literature (Hassell, Am J Prev Med 2010; Lubeck et al., JAMA Network Open 2019; the Multicenter Study of Hydroxyurea, NEJM 1995), CDC Sickle Cell Disease surveillance data, and US newborn-screening data.
- US SCD prevalence (~100,000) verified against Hassell KL, Am J Prev Med 2010 (PMID 20331952)
- Life-expectancy gap (median ~54 vs 76 years) verified against Lubeck et al., JAMA Network Open 2019 (PMID 31730182)
- Hydroxyurea efficacy and underutilisation cross-checked against the Multicenter Study of Hydroxyurea, NEJM 1995 (PMID 7715639) and ASH guidelines
- Demographic and newborn-screening figures cross-referenced against CDC Sickle Cell Disease surveillance data
Frequently asked questions
Commission this assessment
AXLRx US Sickle Cell Disease Disease Landscape is built for commercial, medical affairs, and epidemiology teams that need a rigorous, evidence-based characterisation of the US SCD patient population. Custom assessment in 72 hours.
Use the intake form to specify your indication, geography, and epidemiological focus.
AXLRx analyst confirms subpopulation scope, data sources, and delivery format.
Research-verified assessment in 72 hours with optional analyst readout.